Despite these limitations, we believe that the CD19−/− mouse will be useful for future research on how gut dysbiosis driven by primary antibody deficiency influences gluten-sensitive enteropathies; a rapidly emerging group of related diseases in humans with a currently undefined etiology. The gene discussed is CD19; the disease is agammaglobulinemia.